Effects of spironolactone administration on the podocytes loss and progression of experimental diabetic nephropathy;Efecto de la administración de espironolactona sobre la pérdida de podocitos y la progresión de la nefropatía diabética experimental

Revista Peruana de Medicina Experimental y Salud Publica

Volumn 29, Issue 4, 2012, Pages 490-497

  Aguilar, Cristian ^a   Rodríguez Delfín, Luis ^b,c  

^a HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^b UNIVERSIDAD NACIONAL PEDRO RUIZ GALLO   (Peru)

^c Genética y Biología Molecular GEN MOL   (Peru)

Author keywords

Diabetic nephropathies; Fibrosis; Podocytes; Rats; Spironolactone

Indexed keywords

BUFFER; CITRIC ACID; COLLAGEN; DESMIN; GLUCOSE; MESSENGER RNA; SPIRONOLACTONE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; WT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CELL EXPANSION; CELL LOSS; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; GENE EXPRESSION; GLOMERULAR AREA; GLOMERULAR CELLULARITY; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; MESANGIUM CELL; MORPHOMETRICS; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UROGENITAL SYSTEM PARAMETERS;

EID: 84873953213     PISSN: 17264634     EISSN: 17264642     Source Type: Journal    
DOI: 10.1590/S1726-46342012000400011     Document Type: Article

References (30)

1. Hurtado A, Escudero E, Stromquist CS, Urcia J, Hurtado ME, Gretch D, et al. Distinct patterns of glomerular disease in Lima, Peru. Clin Nephrol. 2000;53(5):325-32.
2. Kriz W, Lemley KV. The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens. 1999;8(4):489-97.
3. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989;38(9):1077-81.
4. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99(2):342-8.
5. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, et al. Urinary excretion of podocytes in patients with diabeticnephropathy. Nephrol Dial Transplant. 2000;15(9):1379-83.
6. Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother. 2007;8(5):529-35.
7. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of Angiotensin Receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2641-50.
8. Lee HS. Pathogenic role of TGF-β in the progression of podocyte diseases. Histol Histopathol. 2011;26(1):107-16.
9. Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, et al. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different satges of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia. 2005;48(12):2650-60.
10. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol. 2004;286(6):F1059-62.
11. Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, et al. Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol. 2002;161(6):2179-93.
12. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70(12):2116-23.
13. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006;1(2):256-62.
14. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28(9):2106-12.
15. Guney I, Selcuk NY, Altintepe L, Atalay H, Başarali MK, Büyükbaş S. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren Fail. 2009;31(9):779-84.
16. Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol. 2008;589(1-3):264-71.
17. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 2004;66(4):1493-502.
18. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocytes as target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49(2):355-64.
19. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem. 1996;29(3):225-9.
20. Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther. 2010;332(3):1072-80.
21. Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, et al. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet. 2002;11(6):651-9.
22. Susztak K, Raff AC, Schiffer M, Böttinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225-33.
23. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant. 2011;26(8):2475-84.
24. Yuan J, Jia R, Bao Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst. 2007;8(3):118-26.
25. Pereira LM, Querido DL, Madeira AC, Mandarim-De-Lacerda CA. Volume-weighted mean glomerular volume in spontaneously hypertensive rats treated with different doses of spironolactone. Int Braz J Urol. 2002;28(4):356-62.
26. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999;56(5):1627-37.
27. Han JS, Choi BS, Yang CW, Kim YS. Aldosterone-induced TGF-beta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells. J Korean Med Sci. 2009;24 Suppl:S195-203.
28. Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, Gandhi NK, et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant. 2005;20(7):1320-8.
29. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005;16(11):3306-14.
30. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98(4):1063-8.